Sign up to save your podcasts
Or
Share #16 Aina Oliver-Caldés: Academic CAR-T cells for myeloma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
#16 Aina Oliver-Caldés: Academic CAR-T cells for myeloma
Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments
worldwide. Aina and colleagues assessed the safety and activity of
ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma.
https://pubmed.ncbi.nlm.nih.gov/37414060/
ALSO AS VIDEO ON
https://youtu.be/Ymgg22roWGU
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari
View all episodes
By The EBMT Trainee CommitteeChimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments
worldwide. Aina and colleagues assessed the safety and activity of
ARI0002h, a BCMA-targeted CAR T-cell therapy developed by academia, in patients with relapsed or refractory multiple myeloma.
https://pubmed.ncbi.nlm.nih.gov/37414060/
ALSO AS VIDEO ON
https://youtu.be/Ymgg22roWGU
CONNECT WITH US
https://twitter.com/TheEBMT_Trainee
https://www.ebmt.org/trainee-committee
https://twitter.com/CarmeloGurnari